Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effects of Reduced and Oxidized CoQ10 on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol

Summary

This randomized, double-blind, placebo-controlled clinical trial will evaluate the effects of Ubiquinol and Ubiquinone on vascular endothelial function in generally healthy adults with borderline high LDL-cholesterol. Participants will receive Ubiquinol 200 mg/day, Ubiquinone 200 mg/day, or placebo for 8 weeks. The primary outcome is change in flow-mediated dilation (FMD), a measure of vascular endothelial function, assessed at baseline, Week 4, and Week 8. The study will also evaluate changes in plasma CoQ10 levels, nitric oxide, LDL oxidation susceptibility, oxidative stress markers, and treatment-emergent adverse events.

Description

Eligibility

Age range

35–65 years

Sex

All

Healthy volunteers

Yes

Interventions

• Dietary Supplement
  Ubiquinol

  Ubiquinol 200 mg/day, administered orally as two soft capsules once daily for 8 weeks. Participants will be instructed to take the capsules with water or warm water after breakfast or lunch containing fat.

• Dietary Supplement
  Ubiquinone

  Ubiquinone 200 mg/day, administered orally as two soft capsules once daily for 8 weeks. Participants will be instructed to take the capsules with water or warm water after breakfast or lunch containing fat.

• Other
  Placebo

  Identical placebo soft capsules administered orally as two capsules once daily for 8 weeks according to the study randomization schedule.

Location